-
- Posts: 14
- Joined: Wed Apr 01, 2009 1:52 pm
Please, help me with finding a solution for the following problem.
I have to fing a % of binding of a set of drug candidates with proteins in blood plasma at concentration levels of 5 and 0.5 ug/ml.
For this purpose, I should develop a method for LC/MS/MS analysis of samples from equilibrium dialysis using the following protocol: www.piercenet.com/files/2034as4.pdf
In brief, according to this protocol, a phosphate buffer is used for sample preparation and the sample after protein precipitation with AcN is subject to LC/MS/MS.
The problem is that, as follows from my preliminary experiments with such model compounds as warfarine and ranitidine, the presence of a phosphate buffer in sample results in a 30-fold sensitivity loss and a chromatographic peak shape degradation (severe tailing and broadening).
I know that phosphate buffer is not recommended for MS/MS, but I can't avoid using it. I have also tried other sample preparation techniques such as LLE and SPE, but it didn't help.
I also observe the peak shape degradation not only using MS/MS, but also using UV detection (UVD is between HLPC and MS/MS systems) - so, this means that phosphate influences also chromatographic efficiency?? It's quite surprising for me.
LC/MS/MS conditions are as follows:
1100 Agilent HPLC + ABI QTrap MS/MS (MRM mode), column Chromolith 4.6x100mm with RP-18e phase, flow rate 2.7 ml/min, split approx. 1:12 prior to injection into MS/MS, injection volume 50 ul, mobile phase 80%ACN with 0.1% FA. For ranitidine determination the run time is about 1 minute, RT of ranitidine is about 0.5 min, the flow is diverted to waste for 0.4 minutes.
Please, advise, what else could we try to solve the problem with peak shape degradation and sensitivity loss in presence of phosphate?
Thank you in advance.
Elena
